The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therap
about
Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 in a patient-derived orthotopic xenograft (PDOX) nude mouse model.Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model
P2860
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therap
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The combination of temozolomid ...... for third-line patient therap
@en
The combination of temozolomid ...... t-derived orthotopic xenograft
@nl
type
label
The combination of temozolomid ...... for third-line patient therap
@en
The combination of temozolomid ...... t-derived orthotopic xenograft
@nl
prefLabel
The combination of temozolomid ...... for third-line patient therap
@en
The combination of temozolomid ...... t-derived orthotopic xenograft
@nl
P2093
P2860
P356
P1433
P1476
The combination of temozolomid ...... for third-line patient therapy
@en
P2093
Arun S Singh
Fritz C Eilber
Irmina A Elliott
Itaru Endo
Kei Kawaguchi
Kentaro Miyake
Mark A Eckardt
Masashi Momiyama
Masuyo Miyake
Michael Bouvet
P2860
P304
103129-103136
P356
10.18632/ONCOTARGET.20789
P407
P577
2017-09-08T00:00:00Z